Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Allergy and Asthma Reports
Published in: Current Allergy and Asthma Reports 8/2020

01-08-2020 | Eosinophilic Esophagitis | Pediatric Allergy and Immunology (W Dolen, Section Editor)

Eosinophilic Esophagitis: Existing and Upcoming Therapies in an Age of Emerging Molecular and Personalized Medicine

Authors: Ian F. Slack, Justin T. Schwartz, Vincent A. Mukkada, Shawna Hottinger, J. Pablo Abonia

Published in: Current Allergy and Asthma Reports | Issue 8/2020

Login to get access

Abstract

Purpose of Review

Recent research efforts have spurred great progress in the diagnosis and management of eosinophilic esophagitis (EoE). Nonetheless, challenges remain in addressing disease burden and impairment in the growing EoE population. We highlight work from the Cincinnati Center for Eosinophilic Disorders, the Consortium of Eosinophilic Gastrointestinal Disease Researchers, and others that address these ongoing challenges.

Recent Findings

New tools for characterizing EoE disease activity include the EoE Histology Scoring System (EoEHSS), endoscopic alternatives, validated patient-reported outcome (PRO) questionnaires, and investigational biomarkers. These diagnostic and monitoring strategies have been complemented by advances in EoE therapy. Treatment modalities have refined the traditional approaches of dietary elimination, swallowed steroids, and proton pump inhibitors (PPI), and biologics offer promise for future treatment.

Summary

This review summarizes EoE advances in disease management and newly defined EoE endotypes that may serve as the foundation for EoE-personalized medicine.
Literature
1.
Kelly KJ, Lazenby AJ, Rowe PC, Yardley JH, Perman JA, Sampson HA. Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula. Gastroenterology. 1995;109(5):1503–12.CrossRefPubMed
2.
• Dellon ES, Liacouras CA, Molina-Infante J, Furuta GT, Spergel JM, Zevit N, et al. Updated International Consensus Diagnostic Criteria for eosinophilic esophagitis: proceedings of the AGREE Conference. Gastroenterology. 2018;155(4):1022–33 e10 Most recent EoE consensus guidelines, incorporating PPI-REE into EoE diagnosis. PubMedCrossRef
3.
Straumann A, Bauer M, Fischer B, Blaser K, Simon HU. Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response. J Allergy Clin Immunol. 2001;108(6):954–61.CrossRefPubMed
4.
Pentiuk S, Putnam PE, Collins MH, Rothenberg ME. Dissociation between symptoms and histological severity in pediatric eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2009;48(2):152–60.PubMedPubMedCentralCrossRef
5.
DeBrosse CW, Collins MH, Buckmeier B, Greenburg A, Allen C, Abonia JP, et al., editors. The “epidemic” of eosinophilic esophagitis (ee) is due to increased recognition of a chronic disorder. J Allergy Clin Immunol; 2010.
6.
Fujiwara Y, Sugawa T, Tanaka F, Tatsuwaki H, Okuyama M, Hayakawa T, et al. A multicenter study on the prevalence of eosinophilic esophagitis and PPI-responsive esophageal eosinophilic infiltration. Intern Med. 2012;51(23):3235–9.CrossRefPubMed
7.
Nantes Castillejo O, Zozaya JM, Jimenez-Perez FJ, Martinez-Penuela JM, Borda F. Incidence and characteristics of eosinophilic esophagitis in adults. An Sist Sanit Navar. 2009;32(2):227–34.PubMed
8.
• Shoda T, Wen T, Aceves SS, Abonia JP, Atkins D, Bonis PA, et al. Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross-sectional study. Lancet Gastroenterol Hepatol. 2018;3(7):477–88 Identifies defined endotypes within EoE. PubMedPubMedCentralCrossRef
9.
Dunn JL, Shoda T, Caldwell JM, Wen T, Aceves SS, Collins MH, et al. Esophageal type 2 cytokine expression heterogeneity in eosinophilic esophagitis in a multi-site cohort. J Allergy Clin Immunol. 2020.
10.
Collins MH, Martin LJ, Alexander ES, Boyd JT, Sheridan R, He H, et al. Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring. Dis Esophagus. 2017;30(3):1–8.PubMed
11.
Hirano I, Collins MH, Assouline-Dayan Y, Evans L, Gupta S, Schoepfer AM, et al. RPC4046, a monoclonal antibody against IL13, reduces histologic and endoscopic activity in patients with eosinophilic esophagitis. Gastroenterology. 2019;156(3):592–603. e10.CrossRefPubMed
12.
• Hirano I, Dellon ES, Hamilton JD, Collins MH, Peterson K, Chehade M, et al. Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology. 2020;158(1):111–22. e10 Phase 2 results of dupilumab in EoE. CrossRefPubMed
13.
Zaccariello MJ, Frank RD, Lee M, Kirsch AC, Schroeder DR, Hanson AC, et al. Patterns of neuropsychological changes after general anaesthesia in young children: secondary analysis of the Mayo Anesthesia Safety in Kids study. Br J Anaesth. 2019;122(5):671–81.PubMedPubMedCentralCrossRef
14.
Postma GN, Cohen JT, Belafsky PC, Halum SL, Gupta SK, Bach KK, et al. Transnasal esophagoscopy: revisited (over 700 consecutive cases). Laryngoscope. 2005;115(2):321–3.CrossRefPubMed
15.
Friedlander JA, DeBoer EM, Soden JS, Furuta GT, Menard-Katcher CD, Atkins D, et al. Unsedated transnasal esophagoscopy for monitoring therapy in pediatric eosinophilic esophagitis. Gastrointest Endosc. 2016;83(2):299–306. e1.CrossRefPubMed
16.
Nguyen N, Lavery WJ, Capocelli KE, Smith C, DeBoer EM, Deterding R, et al. Transnasal endoscopy in unsedated children with eosinophilic esophagitis using virtual reality video goggles. J Clin Gastroenterol Hepatol. 2019;17(12):2455–62.CrossRef
17.
Philpott H, Nandurkar S, Royce SG, Gibson PR. Ultrathin unsedated transnasal gastroscopy in monitoring eosinophilic esophagitis. J Gastroenterol Hepatol. 2016;31(3):590–4.CrossRefPubMed
18.
Iqbal U, Siddique O, Ovalle A, Anwar H, Moss SF. Safety and efficacy of a minimally invasive cell sampling device (‘Cytosponge’) in the diagnosis of esophageal pathology: a systematic review. Eur J Gastroenterol Hepatol. 2018;30(11):1261–9.CrossRefPubMed
19.
Katzka DA, Geno DM, Ravi A, Smyrk TC, Lao-Sirieix P, Miramedi A, et al. Accuracy, safety, and tolerability of tissue collection by Cytosponge vs endoscopy for evaluation of eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2015;13(1):77–83.e2.CrossRefPubMed
20.
Katzka DA, Smyrk TC, Alexander JA, Geno DM, Beitia RA, Chang AO, et al. Accuracy and safety of the cytosponge for assessing histologic activity in eosinophilic esophagitis: a two-center study. Am J Gastroenterol. 2017;112(10):1538–44.PubMedPubMedCentralCrossRef
21.
22.
Hines BT, Rank MA, Wright BL, Marks LA, Hagan JB, Straumann A, et al. Minimally invasive biomarker studies in eosinophilic esophagitis: a systematic review. Ann Allergy Asthma Immunol. 2018;121(2):218–28.PubMedPubMedCentralCrossRef
23.
Mori Y, Iwasaki H, Kohno K, Yoshimoto G, Kikushige Y, Okeda A, et al. Identification of the human eosinophil lineage-committed progenitor: revision of phenotypic definition of the human common myeloid progenitor. J Exp Med. 2009;206(1):183–93.PubMedPubMedCentralCrossRef
24.
Sehmi R, Smith S, Kjarsgaard M, Radford K, Boulet LP, Lemiere C, et al. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma. J Clin Exp Allergy. 2016;46(6):793–802.CrossRef
25.
Morris DW, Stucke EM, Martin LJ, Abonia JP, Mukkada VA, Putnam PE, et al. Eosinophil progenitor levels are increased in patients with active pediatric eosinophilic esophagitis. J Allergy Clin Immunol. 2016;138(3):915–8 e5.PubMedPubMedCentralCrossRef
26.
Henderson A, Magier A, Schwartz JT, Martin LJ, Collins MH, Putnam PE, et al. Monitoring eosinophilic esophagitis disease activity with blood eosinophil progenitor levels. J Pediatr Gastroenterol Nutr. 2020;70(4):482–8.CrossRefPubMedPubMedCentral
27.
Schwartz JT, Morris DW, Collins MH, Rothenberg ME, Fulkerson PC. Eosinophil progenitor levels correlate with tissue pathology in pediatric eosinophilic esophagitis. J Allergy Clin Immunol. 2019;143(3):1221–4. e3.CrossRefPubMed
28.
Thomas G, Goldsmid J, Wicks A. Use of the Enterotest duodenal capsule in the diagnosis of giardiasis. S Afr Med J. 1973;47(11):2219–20.
29.
Furuta GT, Kagalwalla AF, Lee JJ, Alumkal P, Maybruck BT, Fillon S, et al. The oesophageal string test: a novel, minimally invasive method measures mucosal inflammation in eosinophilic oesophagitis. Gut. 2013;62(10):1395–405.CrossRefPubMed
30.
Ackerman SJ, Kagalwalla AF, Hirano I, Gonsalves N, Katcher PM, Gupta S, et al. One-hour esophageal string test: a nonendoscopic minimally invasive test that accurately detects disease activity in eosinophilic esophagitis. Am J Gastroenterol. 2019;114(10):1614–25.PubMedPubMedCentralCrossRef
31.
Patrick DL, Burke LB, Powers JH, Scott JA, Rock EP, Dawisha S, et al. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health. 2007;10:S125–S37.CrossRefPubMed
32.
Schoepfer AM, Straumann A, Panczak R, Coslovsky M, Kuehni CE, Maurer E, et al. Development and validation of a symptom-based activity index for adults with eosinophilic esophagitis. Gastroenterology. 2014;147(6):1255–66.e21.PubMedCrossRef
33.
Schoepfer A, Safroneeva E. Activity assessment of eosinophilic esophagitis. Dig Dis. 2014;32(1–2):98–101.CrossRefPubMed
34.
Aceves SS, King E, Collins MH, Yang GY, Capocelli KE, Abonia JP, et al. Alignment of parent- and child-reported outcomes and histology in eosinophilic esophagitis across multiple CEGIR sites. J Allergy Clin Immunol. 2018;142(1):130–8 e1.PubMedPubMedCentralCrossRef
35.
Franciosi JP, Hommel KA, DeBrosse CW, Greenberg AB, Greenler AJ, Abonia JP, et al. Development of a validated patient-reported symptom metric for pediatric eosinophilic esophagitis: qualitative methods. BMC Gastroenterol. 2011;11:126.PubMedPubMedCentralCrossRef
36.
Franciosi JP, Hommel KA, Bendo CB, King EC, Collins MH, Eby MD, et al. PedsQL eosinophilic esophagitis module: feasibility, reliability, and validity. J Pediatr Gastroenterol Nutr. 2013;57(1):57–66.PubMedPubMedCentralCrossRef
37.
Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113(1):59–65.CrossRefPubMed
38.
Arias A, Gonzalez-Cervera J, Tenias JM, Lucendo AJ. Efficacy of dietary interventions for inducing histologic remission in patients with eosinophilic esophagitis: a systematic review and meta-analysis. Gastroenterology. 2014;146(7):1639–48.CrossRefPubMed
39.
Markowitz JE, Spergel JM, Ruchelli E, Liacouras CA. Elemental diet is an effective treatment for eosinophilic esophagitis in children and adolescents. Am J Gastroenterol. 2003;98(4):777–82.CrossRefPubMed
40.
Gonsalves N. Food allergies and eosinophilic gastrointestinal illness. Gastroenterol Clin North Am. 2007;36(1):75–91 vi.CrossRefPubMed
41.
Kagalwalla AF, Sentongo TA, Ritz S, Hess T, Nelson SP, Emerick KM, et al. Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2006;4(9):1097–102.CrossRefPubMed
42.
Spergel JM, Brown-Whitehorn TF, Cianferoni A, Shuker M, Wang ML, Verma R, et al. Identification of causative foods in children with eosinophilic esophagitis treated with an elimination diet. J Allergy Clin Immunol. 2012;130(2):461–7 e5.CrossRefPubMed
43.
Lucendo AJ, Arias A, Gonzalez-Cervera J, Yague-Compadre JL, Guagnozzi D, Angueira T, et al. Empiric 6-food elimination diet induced and maintained prolonged remission in patients with adult eosinophilic esophagitis: a prospective study on the food cause of the disease. J Allergy Clin Immunol. 2013;131(3):797–804.CrossRefPubMed
44.
Dellon ES, Gonsalves N, Hirano I, Furuta GT, Liacouras CA, Katzka DA, et al. ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol. 2013;108(5):679–92.CrossRefPubMed
45.
Henderson CJ, Collins MH, Abonia JP, Putnam PE, Rothenberg ME. Reply: To PMID 22541246. J Allergy Clin Immunol. 2013;131(1):243–4.CrossRefPubMed
46.
Henderson CJ, Abonia JP, King EC, Putnam PE, Collins MH, Franciosi JP, et al. Comparative dietary therapy effectiveness in remission of pediatric eosinophilic esophagitis. J Allergy Clin Immunol. 2012;129(6):1570–8.PubMedPubMedCentralCrossRef
47.
Chehade M, Jones SM, Pesek RD, Burks AW, Vickery BP, Wood RA, et al. Phenotypic characterization of eosinophilic esophagitis in a large multicenter patient population from the consortium for food allergy research. J Allergy Clin Immunol Pract. 2018;6(5):1534–44 e5.PubMedPubMedCentralCrossRef
48.
Wolf WA, Huang KZ, Durban R, Iqbal ZJ, Robey BS, Khalid FJ, et al. The six-food elimination diet for eosinophilic esophagitis increases grocery shopping cost and complexity. Dysphagia. 2016;31(6):765–70.CrossRef
49.
Kagalwalla AF, Wechsler JB, Amsden K, Schwartz S, Makhija M, Olive A, et al. Efficacy of a 4-food elimination diet for children with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2017;15(11):1698–707. e7.PubMedPubMedCentralCrossRef
50.
Molina-Infante J, Arias A, Barrio J, Rodriguez-Sanchez J, Sanchez-Cazalilla M, Lucendo AJ. Four-food group elimination diet for adult eosinophilic esophagitis: a prospective multicenter study. J Allergy Clin Immunol. 2014;134:1093–1099.e1.CrossRefPubMed
51.
Molina-Infante J, Arias A, Alcedo J, Garcia-Romero R, Casabona-Frances S, Prieto-Garcia A, et al. Step-up empiric elimination diet for pediatric and adult eosinophilic esophagitis: the 2-4-6 study. J Allergy Clin Immunol. 2018;141(4):1365–72.CrossRefPubMed
52.
Cincinnati Children’s Hospital Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Allergy and Infectious Diseases, Office of Rare Diseases, National Center for Advancing Translational Science. SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study. https://​ClinicalTrials.​gov/​show/​NCT02778867; 2016.
53.
54.
Dellon ES, Woosley JT, Arrington A, McGee SJ, Covington J, Moist SE, et al. Efficacy of budesonide vs fluticasone for initial treatment of eosinophilic esophagitis in a randomized controlled trial. Gastroenterology. 2019;157(1):65–73. e5.CrossRefPubMed
55.
Gupta SK, Vitanza JM, Collins MH. Efficacy and safety of oral budesonide suspension in pediatric patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2015;13(1):66–76. e3.CrossRefPubMed
56.
Murali AR, Gupta A, Attar BM, Ravi V, Koduru P. Topical steroids in eosinophilic esophagitis: systematic review and meta-analysis of placebo-controlled randomized clinical trials. J Gastroenterol Hepatol. 2016;31(6):1111–9.CrossRefPubMed
57.
Alexander JA, Jung KW, Arora AS, Enders F, Katzka DA, Kephardt GM, et al. Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2012;10(7):742–9. e1.CrossRefPubMed
58.
Ryrfeldt Å, Andersson P, Edsbäcker S, Tönnesson M, Davies D, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis. 1982;122:86–95.
59.
60.
Golekoh MC, Hornung LN, Mukkada VA, Khoury JC, Putnam PE, Backeljauw PF. Adrenal insufficiency after chronic swallowed glucocorticoid therapy for eosinophilic esophagitis. J Pediatr. 2016;170:240–5.CrossRefPubMed
61.
Hsu S, Wood C, Pan Z, Rahat H, Zeitler P, Fleischer D, et al. Adrenal insufficiency in pediatric eosinophilic esophagitis patients treated with swallowed topical steroids. Pediatr Allergy Immunol Pulmonol. 2017;30(3):135–40.PubMedPubMedCentralCrossRef
62.
Cotton CC, Eluri S, Wolf WA, Dellon ES. Six-food elimination diet and topical steroids are effective for eosinophilic esophagitis: a meta-regression. Dig Dis Sci. 2017;62(9):2408–20.PubMedPubMedCentralCrossRef
63.
Furuta GT, Liacouras CA, Collins MH, Gupta SK, Justinich C, Putnam PE, et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology. 2007;133(4):1342–63.CrossRefPubMed
64.
Liacouras CA, Furuta GT, Hirano I, Atkins D, Attwood SE, Bonis PA, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol. 2011;128(1):3–20 e6 quiz 1-2.
65.
Spechler SJ, Genta RM, Souza RF. Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis. Am J Gastroenterol. 2007;102(6):1301–6.CrossRefPubMed
66.
Dellon ES, Speck O, Woodward K, Gebhart JH, Madanick RD, Levinson S, et al. Clinical and endoscopic characteristics do not reliably differentiate PPI-responsive esophageal eosinophilia and eosinophilic esophagitis in patients undergoing upper endoscopy: a prospective cohort study. Am J Gastroenterol. 2013;108(12):1854–60.PubMedPubMedCentralCrossRef
67.
Wen T, Dellon ES, Moawad FJ, Furuta GT, Aceves SS, Rothenberg ME. Transcriptome analysis of proton pump inhibitor–responsive esophageal eosinophilia reveals proton pump inhibitor–reversible allergic inflammation. J Allergy Clin Immunol. 2015;135(1):187–97. e4.CrossRefPubMed
68.
Wang L, Li M, Cao Y, Han Z, Wang X, Atkinson EJ, et al. Proton pump inhibitors and the risk for fracture at specific sites: data mining of the FDA adverse event reporting system. Sci Rep. 2017;7(1):5527.PubMedPubMedCentralCrossRef
69.
70.
Stein ML, Collins MH, Villanueva JM, Kushner JP, Putnam PE, Buckmeier BK, et al. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol. 2006;118(6):1312–9.CrossRefPubMed
71.
Straumann A, Conus S, Grzonka P, Kita H, Kephart G, Bussmann C, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut. 2010;59(01):21–30.CrossRefPubMed
72.
Assa’ad AH, Gupta SK, Collins MH, Thomson M, Heath AT, Smith DA, et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology. 2011;141(5):1593–604.CrossRefPubMed
73.
Spergel JM, Rothenberg ME, Collins MH, Furuta GT, Markowitz JE, Fuchs G 3rd, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2012;129(2):456–63 63 e1–3.CrossRefPubMed
74.
Ghazi A, Trikha A, Calhoun WJ. Benralizumab–a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity–a novel approach for the treatment of asthma. Expert Opin Biol Ther. 2012;12(1):113–8.CrossRefPubMed
75.
Nutku E, Aizawa H, Hudson SA, Bochner BS. Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood. 2003;101(12):5014–20.CrossRefPubMed
76.
77.
78.
Zuo L, Fulkerson PC, Finkelman FD, Mingler M, Fischetti CA, Blanchard C, et al. IL-13 induces esophageal remodeling and gene expression by an eosinophil-independent, IL-13Rα2–inhibited pathway. J Immunol. 2010;185(1):660–9.PubMedCrossRef
79.
Blanchard C, Mingler MK, Vicario M, Abonia JP, Wu YY, Lu TX, et al. IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids. J Allergy Clin Immunol. 2007;120(6):1292–300.CrossRefPubMed
80.
Rothenberg ME, Wen T, Greenberg A, Alpan O, Enav B, Hirano I, et al. Intravenous anti–IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015;135(2):500–7.CrossRefPubMed
81.
Dellon ES, Collins MH, Rothenberg ME, Assouline-Dayan Y, Evans L, Gupta S, et al. Long-term efficacy and tolerability of RPC4046 in an open-label extension trial of patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2020.
82.
Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455–66.CrossRefPubMed
83.
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–48.CrossRefPubMed
84.
Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315(5):469–79.CrossRefPubMed
85.
Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–96.CrossRefPubMed
86.
Vermeire S, Loftus EV, Colombel J-F, Feagan BG, Sandborn WJ, Sands BE, et al. Long-term efficacy of vedolizumab for Crohn’s disease. Journal of Crohn’s Colitis. 2017;11(4):412–24.PubMed
87.
Rafiee P, Ogawa H, Heidemann J, Li MS, Aslam M, Lamirand TH, et al. Isolation and characterization of human esophageal microvascular endothelial cells: mechanisms of inflammatory activation. Am J Physiol Gastrointest Liver Physiol. 2003;285(6):G1277–G92.CrossRefPubMed
88.
Nhu QM, Chiao H, Moawad FJ, Bao F, Konijeti GG. The anti-alpha4beta7 integrin therapeutic antibody for inflammatory bowel disease, vedolizumab, ameliorates Eosinophilic esophagitis: a novel clinical observation. Am J Gastroenterol. 2018;113:1261–3.CrossRefPubMed
89.
Taft TH, Mutlu EA. The potential role of vedolizumab in concomitant eosinophilic esophagitis and Crohn’s disease. Clin Gastroenterol Hepatol. 2018;16(11):1840–1.CrossRefPubMed
90.
Kim HP, Reed CC, Herfarth HH, Dellon ES. Vedolizumab treatment may reduce steroid burden and improve histology in patients with eosinophilic gastroenteritis. Clin Gastroenterol Hepatol. 2018;16(12):1992–4.PubMedPubMedCentralCrossRef
91.
Abonia JP, Wen T, Stucke EM, Grotjan T, Griffith MS, Kemme KA, et al. High prevalence of eosinophilic esophagitis in patients with inherited connective tissue disorders. J Allergy Clin Immunol. 2013;132(2):378–86.CrossRefPubMed
92.
93.
Meester JA, Verstraeten A, Schepers D, Alaerts M, Van Laer L, Loeys BL. Differences in manifestations of Marfan syndrome, Ehlers-Danlos syndrome, and Loeys-Dietz syndrome. Ann Cardiothorac Surg. 2017;6(6):582–94.PubMedPubMedCentralCrossRef
94.
Ruiz-Ortega M, Rodríguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J. TGF-β signaling in vascular fibrosis. Cardiovasc Res. 2007;74(2):196–206.CrossRefPubMed
95.
Ferguson AE, Mukkada VA, Fulkerson PC. Pediatric eosinophilic esophagitis endotypes: are we closer to predicting treatment response? Clin Rev Allergy Immunol. 2017.
96.
Wen T, Stucke EM, Grotjan TM, Kemme KA, Abonia JP, Putnam PE, et al. Molecular diagnosis of eosinophilic esophagitis by gene expression profiling. Gastroenterology. 2013;145(6):1289–99.PubMedCrossRef
97.
Dellon ES. Epidemiology of eosinophilic esophagitis. Gastroenterol Clin. 2014;43(2):201–18.CrossRef
Metadata
Title
Eosinophilic Esophagitis: Existing and Upcoming Therapies in an Age of Emerging Molecular and Personalized Medicine
Authors
Ian F. Slack
Justin T. Schwartz
Vincent A. Mukkada
Shawna Hottinger
J. Pablo Abonia
Publication date
01-08-2020
Publisher
Springer US
Published in
Current Allergy and Asthma Reports / Issue 8/2020
Print ISSN: 1529-7322
Electronic ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-020-00928-2

Other articles of this Issue 8/2020

Current Allergy and Asthma Reports 8/2020 Go to the issue

Telemedicine and Technology (J Portnoy, Section Editor)

Wearable Technology and How This Can Be Implemented into Clinical Practice

Pediatric Allergy and Immunology (W Dolen, Section Editor)

Proton Pump Inhibitors in Children: the Good, the Bad, and the Ugly

Asthma (V Ortega, Section Editor)

Occupational Exposure to Metals and Solvents: Allergy and Airway Diseases

Basic and Applied Science (I Lewkowich, Section Editor)

The Role of New IL-1 Family Members (IL-36 and IL-38) in Atopic Dermatitis, Allergic Asthma, and Allergic Rhinitis

Otitis (D Skoner, Section Editor)

Allergy and Otitis Media in Clinical Practice

Allergic Skin Diseases (L Fonacier and A Wollenberg, Section Editors)

Biologics for Allergic Dermatologic Diseases